Common data elements to standardize genomics studies in cerebral palsy.
Yana A Wilson, Hayley Smithers-Sheedy, Katarina Ostojic and 7 others
PMID 35441707WHAT IT FOUND
Researchers developed a standardized data set for cerebral palsy genomics studies, defining 10 mandatory items like birth year, sex, motor type, and GMFCS level.
This framework helps unify how clinical traits are recorded globally, though it excludes intervention data.
Key findings
01The final minimum data set for cerebral palsy genomics consists of 10 mandatory data elements, including year of birth, sex, country, movement disorder presence, degenerative course, Human Phenotype Ontology traits, predominant motor type, laterality, GMFCS level, and epilepsy status.
02The broader common data elements include 107 items across six categories, but explicitly exclude data on interventions, treatments, and therapies.
03Consensus was reached using a three-round Delphi process with 46 initial respondents, where over 75% agreement was required to define the hierarchy of data elements.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The CDEs explicitly exclude data on interventions, treatments, and therapies, limiting their utility for clinical effectiveness studies. Consensus was not achieved for all data elements; the steering committee assigned hierarchy levels for 28 residual elements based on raw scores. The response rate for the initial Delphi round was 47.4% (37 of 78 invited panelists plus 9 from another academy), which may introduce selection bias. The study is designed for genomics research and may not capture all clinically relevant phenotypic nuances needed for individual patient management.
Declared interests
The authors report no specific conflicts of interest in the provided text, but the study was supported by the National Institutes of Health (NIH) and non-U.S. government sources. The funder 'PTC Therapeutics' is listed in the funding section, which is a pharmaceutical company involved in rare disease treatments.
The easy way to misread this
Do not use this minimum data set as a clinical assessment tool for patient care. It is designed for research harmonization in genomics studies and explicitly excludes intervention and therapy data, so it is not suitable for guiding individual treatment plans.